Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report.
Anticancer Drugs
; 35(9): 872-874, 2024 Oct 01.
Article
en En
| MEDLINE
| ID: mdl-39008456
ABSTRACT
We present a case of a patient diagnosed with FLT3 mut+ acute myeloid leukemia with FLT3 and NMP1 mutations who did not respond to standard induction and consolidation treatment with chemotherapy. Due to the FLT3mut+ gene mutation and intermediate cytogenetic risk, treatment with gilteritinib is requested. After treatment she experienced a neutrophilic dermatosis and granuloma annulare that was resolved with gilteritinib dose reduction and specific treatment in coordination with the dermatology department.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Leucemia Mieloide Aguda
/
Tirosina Quinasa 3 Similar a fms
/
Compuestos de Anilina
/
Mutación
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Anticancer Drugs
Asunto de la revista:
ANTINEOPLASICOS
Año:
2024
Tipo del documento:
Article
País de afiliación:
España